Application
PHA 767491 hydrochloride has been used to study its effect on estrogen-induced DNA damage. It has also been used in western blot analysis and to study the S9.6 nuclear signal in HeLa cells.
Biochem/physiol Actions
PHA 767491 serves as a potential anticancer drug. It shows an ameliorating effect against acute myeloid leukemia, colon and breast cancer models. PHA 767491 possesses anti proliferating and apoptotic effect.
PHA-767491 is a potent and selective ATP-competitive dual inhibitor cdc7/cdk9. PHA-767491 blocks DNA synthesis and affects the phosphorylation of the replicative DNA helicase at Cdc7-dependent phosphorylation sites.
Other Notes
This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.
To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.
- UPC:
- 51183706
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- PZ0178-25MG
- CAS:
- 845538-12-7
